^
Association details:
| Biomarker: | BRCA2 mutation |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | venadaparib (NOV 1401) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
270P - Phase Ib study of venadaparib, a potent and selective PARP inhibitor, in homologous recombination repair (HRR) mutated breast cancer
Published date:
09/13/2021
Excerpt:
Metastatic breast cancer (mBC) patients with pathogenic germline BRCA 1/2 (gBRCA1/2) mutation, somatic BRCA 1/2 (sBRCA 1/2), ATM, PALB2, or RAD51C were enrolled….Patients were administered with venadaparib doses ranging from 120mg to 240mg, based on emerging data from ongoing phase 1a dose finding study....Of the 10 evaluable patients (8 gBRCAmt and 2 sBRCAmt), 1 patient had complete response (CR), 7 patients had partial responses (PR) and 2 patients had stable disease (SD), leading to 80% ORR and 100% DCR.
Trial ID:
